|
Powered by Cell Signaling Technology |
Site Information |
---|
LIDsMANsFVGTRSY SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 448513 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Regulatory protein: | |
Putative upstream phosphatases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on MEK1: | |
Effects of modification on biological processes: |
References | |
---|---|
Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA (2015) p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 34, 589-99
24469052 Curated Info |
|
Makdissy N, et al. (2015) Regulation of SREBPs by Sphingomyelin in Adipocytes via a Caveolin and Ras-ERK-MAPK-CREB Signaling Pathway. PLoS One 10, e0133181
26230734 Curated Info |
|
Cam M, et al. (2014) p53/TAp63 and AKT Regulate Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling through Two Independent Parallel Pathways in the Presence of DNA Damage. J Biol Chem 289, 4083-94
24366874 Curated Info |
|
Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750 Curated Info |
|
Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622 Curated Info |
|
Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356 Curated Info |
|
Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096 Curated Info |
|
Packer LM, et al. (2011) Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 20, 715-27
22169110 Curated Info |
|
Andreu-PĂ©rez P, et al. (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4, ra58
21917714 Curated Info |
|
Guo A (2011) CST Curation Set: 12478; Year: 2011; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |
|
Feng X, et al. (2011) Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 12, 544-50
21532575 Curated Info |
|
Wang Y, et al. (2011) Spatial phosphoprotein profiling reveals a compartmentalized extracellular signal-regulated kinase switch governing neurite growth and retraction. J Biol Chem 286, 18190-201
21454597 Curated Info |
|
Kim DS, et al. (2011) Sphingosine-1-phosphate decreases melanin synthesis via microphthalmia-associated transcription factor phosphorylation through the S1P3 receptor subtype. J Pharm Pharmacol 63, 409-16
21749389 Curated Info |
|
Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079 Curated Info |
|
Chandrakesan P, et al. (2010) Novel changes in NF-{kappa}B activity during progression and regression phases of hyperplasia: role of MEK, ERK, and p38. J Biol Chem 285, 33485-98
20710027 Curated Info |
|
Tucker M (2010) CST Curation Set: 9080; Year: 2010; Biosample/Treatment: cell line, embryonic stem cells (mouse)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980
Curated Info |
|
Tucker M (2009) CST Curation Set: 8601; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Tucker M (2009) CST Curation Set: 8604; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Tucker M (2009) CST Curation Set: 8603; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Tucker M (2009) CST Curation Set: 8605; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Tucker M (2009) CST Curation Set: 8602; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Tucker M (2009) CST Curation Set: 8600; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7443; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7440; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7442; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7413; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7418; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7414; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7412; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Zhou J (2009) CST Curation Set: 7411; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info |
|
Oneyama C, et al. (2008) The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src. Mol Cell 30, 426-36
18498747 Curated Info |
|
Ding B, Lengyel P (2008) p204 protein is a novel modulator of ras activity. J Biol Chem 283, 5831-48
18165224 Curated Info |
|
Xuan YT, et al. (2007) Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116, 535-44
17606840 Curated Info |
|
Chien Y, et al. (2006) RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-70
17018283 Curated Info |
|
Mitra SK, et al. (2006) Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 25, 5969-84
16682956 Curated Info |
|
Yang X, et al. (2005) The FLT3 Internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res 65, 7338-47
16103085 Curated Info |
|
Takahashi S, et al. (2005) Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling. Proc Natl Acad Sci U S A 102, 1737-42
15665076 Curated Info |
|
Valjent E, et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A 102, 491-6
15608059 Curated Info |
|
Hayne C, Xiang X, Luo Z (2004) MEK inhibition and phosphorylation of serine 4 on B23 are two coincident events in mitosis. Biochem Biophys Res Commun 321, 675-80
15358159 Curated Info |
|
Sinnett-Smith J, et al. (2004) Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells. J Biol Chem 279, 16883-93
14963034 Curated Info |
|
Kovalenko D, et al. (2003) Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation. J Biol Chem 278, 14087-91
12604616 Curated Info |
|
Demoulin JB, et al. (2003) MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 22, 1763-70
12660812 Curated Info |
|
Cross MJ, et al. (2002) The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol Biol Cell 13, 2881-93
12181353 Curated Info |
|
Rovida E, Baccarini M, Olivotto M, Sbarba PD (2002) Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages. Oncogene 21, 3670-6
12032835 Curated Info |
|
Welch DR, et al. (2000) Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res 60, 1552-6
10749122 Curated Info |
|
Pham CD, et al. (1995) Characterization of MEK1 phosphorylation by the v-Mos protein. Oncogene 10, 1683-8
7731726 Curated Info |
|
Huang W, Erikson RL (1994) Constitutive activation of Mek1 by mutation of serine phosphorylation sites. Proc Natl Acad Sci U S A 91, 8960-3
8090753 Curated Info |